Skip to content

Author

Gregory A. Jicha

We have 4 of 30 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Incident versus prevalent progressive supranuclear palsy: analyses of U.S. Alzheimer’s Disease Research Centers data indicate clinical and neuropathological features of a relatively common and underrecognized tauopathy in the aging brain

In this large multicenter sample, PSP pathology was more common than other FTLD-Tau subtypes, and incident PSP often differed clinically from “classic” PSP, and PSP tau pathology was more severe overall in prevalent PSP.

Benjamin J. Cushing, Ryan K. Shahidehpour, E. Abner et al. · 0 citations
Open access Sep 2026

Rare extreme polygenic risk scores strongly indicate Alzheimer’s disease risk

Background. Alzheimer's disease (AD) pathology often accumulates years before memory loss, creating a need to identify high-risk individuals presymptomatically. Polygenic risk scores (PRS) stratify AD risk, but individual-level predictions remain uncertain. Extreme PRS may identify high-risk individuals independent of...

Elizabeth L. Ward, Peter T. Nelson, Y. Katsumata et al. · 0 citations
Open access Sep 2026

Alzheimer’s Polygenic Risk Scores Are Not Interchangeable: Evidence from 1,752 Models

Introduction: Polygenic risk scores (PRS) may improve Alzheimer's disease (AD) risk prediction before symptom onset, yet choosing an appropriate model can be challenging. Methods: Using the standardized GenoPred pipeline, 1,752 PRS models (9 algorithms; 584 configurations; 3 genome-wide association studies) were evalua...

Elizabeth L. Ward, Peter T. Nelson, Y. Katsumata et al. · 0 citations
Review Aug 2026

TDP-43-Associated Neurodegenerative Disease Conceptualization and Integrated Staging: A Review.

A pathobiological definition of disease is proposed to provide a road map for developing biomarkers that accurately reflect the underlying pathobiology of disease and for advancing therapeutic candidates that effectively target fundamental disease mechanisms.

M. Benatar, SJ Barmada, Gregory A. Jicha et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.